32.jpg)
56.jpg)
MOXIFLOXACIN FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY
WO20234496
The identification of a new valid molecule to develop a new therapy for the prevention and/or treatment of spinal muscular atrophy (SMA). Moxifloxacin has been found to significantly increase SMN protein levels, one avenue of treatment for spinal muscular atrophy. Moxifloxacin has demonstrated efficacy as an antibiotic when administered by oral, injectable and ophthalmic routes, offering for SMA the possibility of less invasive administration than currently used treatments. In addition, its lower cost would allow the development of a treatment with distribution of the drug throughout the body, which would help to alleviate not only the neurological effects, but also the other alterations that also occur in this disease.
Applications The main application of the technology is in the pharmaceutical sector as an active ingredient for the treatment of Spinal Muscular Atrophy. Competitive advantages The main advantages provided by the invention are: Non-invasive administration: oral, injectable, ophthalmic. Systemic distribution, which makes it possible to combat not only neurological signs but also other problems associated with the disease. Lower cost compared to existing treatments.